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and placebo periods, patients were randomized into 5 groups for 3 weeks: 
placebo, Mib 25/50 rag, 501100 rag, 100/150 mg or amlodipine (Am) 5/10 mg. 
In addition, ET duration and duration of daily silent ischemia improved 
significantly only by Mib 50/100 and 100/150 rag. Both Mib and Am were well 
tolerated. 
Conclusion: Mibefradil given once daily is a highly effective in suppressing 
exercise and daily ischemia, 
4:30 
~ T h e  of  Exercise Capacity in the Importance 
Interpretation o f  an Ischeml¢ Response to Exercise 
Testing 
John R Murphy, Michael G. Kahn, Ronald J. Krone. MMIR Group 
Washington Univereily School of Medicine, St. Louis, MO 
We sought o determine the influence of exercise capacity on risk stratification 
in patients with positive exercise thallium tests. The pdmary trial (Muificentar 
Myocardial Ischemia Research Group) of 936 patients with stable coronary 
artery disease who had exercise thallium testing and were followed for 23 
months has already been reported. We stratified patients by beth ECG 
results and exercise capacity, and baseline variables were compared among 
groups. Kaplan-Malar event curves were calculated for the primary outcome, 
the combination of unstable angina, myocardial infarction, or cardiac death. 
For event cuwes for patients stratified by ECG results and stage three, p 
= 0.0004. For patients stratified by overall thallium result and stage 3, p 
= 0.0083. Seen below, the combination of both a positive test and limited 
exercise capacity predicts inoreesed risk. 
Event rate, ECG 1 yr 2 yr Event rate, Thallium I yr 2 Yr 
Positive, < $3 23°/. 33% Positive. < S3 20% 28% 
Positive, ~ $3 9% 13% Positive, > $3 11% 19% 
Negative, < $3 11% 16% Negative, < $3 10% 17% 
Negative, >_ $3 14% 19% Negative, > $3 13% 17% 
Event rates for patients with a positive ECG or thallium test but able to 
reach stage 3 are not different from those of patients with negative ECG 
and thallium tests, Thus, preserved exercise capacity identifies patients at 
low dsk for cardiac events despite an ischercio response to exercise thallium 
testing. 
4:45 
~'~- - ]  Cost Implications for Treatment of Cardiac 
Ischemla: An Ancil lary AsymptomaticCardlac 
Isehemla Pilot (ACIP) Study 
Cad J. Pepine, Daniel Mark, Martial Bourassa, Bemard Chairman, 
Geneil Knatterud, Sandra Forman, Craig Pratt, George Bopko, C. 
Richard Conti. Universily of Florida, Gainesville, FL 
Economic implications for ischemia management were studied in 558 pts 
randomized to one of three initial treatment strategies (aegina-guided in = 
183] or Ischemia-gulded (n= 183] medical care or revasculadzation i  = 192]). 
Cost data for events and procedure-related hospitalizations were assigned 
using Medicare diagnosis-related-group (DRG) reimbursement rates in 1993 
dollars, As expected, resource consumption for the initial yr of care was 
considerably higher with revascularization ($13,030) compared with angina- 
and Ischemie-gutded medical strate@es ($4,265 and $4,692/pt enrolled). 
There were significantly more nonprotocol revescuierization procedures and 
events in the medical strategies compared with revascularization, so cost/pt 
for the last 6 rags of the first yre care was greater for the medical strategies 
($1,314 and $2,074) than ravasoularization ($204). If these costs differences 
can be extrapolated through future follow-up yrs then the costs of medical 
strategies could reasWexceeq costs of revasoularization in 4 to 6 yre because 
of the expense of additional events in the medical strategies. 
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Thus revesculadzation may prove, with additional follow-up, to be cost 
effective or even cost saving relative to an initial medical strategy to manage 
ischemla. 
5:00 
~ - ~  Combination Therapy With Metoprolo l  and 
Nifedipine Doesn't Have Addit ive AntHschemic 
Effect in individual Patients With Stable Angina 
Pectoris 
Stefano Savonitto, Diego Ardissir,o, Kenneth Egstrup, Inger Wahlqvist, 
Piera A. Madini, Nina Rehnqvist. Milan, Italy for the IMAGE study group 
It is not dear whether combined therapy with metoprolol (M) (which reduces 
oxygen consumption) and nlfediplne (N) (which increases coronary flow) has 
an additive effect in 10Is with stable angina. In a double blind trial 280 pts 
were enrolled in 25 European Centers. After a 2-week placebo (PI) (wk 0), 
10ts were randomtsod to M 200 mg o.d. or N 20 mg b.Ld. for 6 wks; then, they 
randomly added PI or the altsmative drag for a further 4 wks. Exercise tests 
were performed at wks 0, 6 and 10. 248 patients completed the study. At wk 
6, M increased time to -1 mm ST depression (TST) by 70" (95% CI 47 to 
92") in comparison with wk 0, and N by 43" (16 to 69) (both p < 0.01 vs wk 
0; p < 0.05 M vs N). At wk 10, those pts adding PI did not change their mean 
exercise tolerance further, while those adding N to M had a further increase 
(p < 0.05 vs PI) to achieve a gain of 108" (71 to 145") from wk 0, and those 
adding M to N achieved a gain of 107" (64 to 151 ") from wk 0 (p < 0.C5 vs PI). 
However, this mean additive effect of combined therapy was not due to an 
additive effect in individual pts. In fact, only 6% of the pts in the M + N group 
and 6% in the N + M group increased TaT >_ 15% of their basaline value 
both dudng monotherapy anddudng combined therapy, vs 6% in the M ÷ PI 
group and 3% in the N + PI group (all p = ns). Moat of the additive effect in 
the combination groups was due to a "recruitment" of responders (increase 
in TaT > 15°/@ from the value at wk 6) by the 2nd drug when the 1st had 
been ineffective: 10% with M + N, 25% with N + M (p < 0.05 vs N + PI), 12°/@ 
with M + PI and 10% with N + PI. Thus, in a group of pts with stable angina, 
combined therapy with M and N improves exercise tolerance compared with 
monotherapy. However, this effect is not due to an additive effect in individual 
lOtS, but to a "recruitment" of tots non responders to monotherapy. 
5:15 
~"6"~"[  Randomized Trial o f  AnUdepreesants In Patients 
With lachemlc Heart Disease 
Mitchell S. Finkal, Andrew Gaffney, Pouzia Laghfissi-Thode, Bruce 
G. Pollock, John Kennedy, Craig Nelson, Ivan Gergel, James R McCaffedy, 
Stevon R Roo~;e. Univemity of Pittsburgh, Pittsburgh, PAl Vanderbilt 
University, Nashville, TN 
Clinical depression following myocardial infarction has recently been identi- 
fied as an independent risk factor for subsequent cardiac death. The Cardiac 
Arrhythmia Suppression Trial raised serious concerns about the use of tri- 
cyclic antidepressants 0"CA) in patients with ischemic heart disease (IHD) 
in view of their Class IA antiarrhythmio properties. Little systematic data are 
available on the cardiac effects of selective serotonin reuptaKe inhlbifore 
($SRI). Accordingly, we conducted the first prospective, randomized, clinical 
trial of the safety and efficacy of the SSRI, Paroxetlne (Px), and the TCA, 
Norldptyline (Nt), in IHD. 41 IHO patients received Px and 40 Nt for treat- 
ment of clinical depression based on a Hamilton Depression Scale (HAM-O) 
score of > 17. Over 80% of the patients in both groups were taking cardiac 
medications including beta blockers and espldn. Antidepressant efficacy was 
similar in both groups with 73% of Nt and 66% of Px patients achieving > 
50% reduction in HAM-D over the 6 week study period. Supine pulse rates 
increased from 70:1= 2 to 78 ± 2 in Nt patients with no ch~.nge in Px patients 
(66 ± 2 vs. 66 a- 1). 37/41 Px and 26/40 Nt completed week 6. 8/40 Nt and 
2/41 Px were withdrawn due to adverse events, including 7 Nt cardiac events 
despite optimal blood levels (unstable angina, dysrhythmie) end 1 Px with 
palpitations. We conclude that depressed patients with IHD can be effectively 
treated with either Nt or Px. However, Px appears to be better tolerated with 
fewer adverse cardiac effects in IHD. 
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4:00 
{"7~'- 1 -~ Natural History of  Hypertrophic Cardlomyopathy 
During Childhood Revisited in an Unselectsd 
Community-Based Populat ion 
David A. Burton, Liviu C. Pollac, Barry J. Maron. Children's Heart Clinic and 
Minneapolis Heart Institute Foundation, Minneapolis, MN 
Clinical course of hypertrophic cardiomyopathy (HCM) in childhood has been 
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judged particulady unfavorable with annual morality rates reported Up to 
6%o. However, prior studies were confined to pte referred to tertiary centers, 
selectively focused on high-risk assessment. To analyze natural history inde- 
pendent of such selection bias, we studied a cohort of 25 children identified 
with HCM from a community-based practice since 1972. Initially ages were 
0.5-18 yre (mean 6): 15 (60%) were male. Eight lots (32%) had basal out- 
flow obstruction with gradients 35-125 mm Hg; LV wall thicknesses were 
substantial, 10-40 rnm (mean 22), with a variety of patterns of left vantric- 
ular hypertrophy (LVH) evident. During foltow-up (1-21 yrs; mean 8), 4 pts 
died suddenly, aged 7-t9 yrs including 1 each after myofomy-myectomy or 
defibrillator implant. Each of the 4 tots with sudden death had massive LVH 
(wall thicknesses 40, 38, 31, 25 mm at ages 7, 7, 19, 10 years). Annual 
mortality rate was 2.0%; survival was 90% at 5 yrs. Eight surviving pts devel- 
obed limiting symptoms, including 4 who underwent myotcmy-myectomy. In 
conclusion: 1) HCM in childhood may be associated with substantial morbid- 
try/mortality; 2) dsk for youthful sudden death was substantially lower in this 
unestscted population represen~tive of the true disease state, than reported 
from referral canters; 3) massive LVH may be an independent dsk factor 
for sudden death in young children with HCM, suggesting the possibility of 
aggressive management for this patient subgroup, 
4:15 
~ Timing of Intervention for  Restrictive 
Cardiomyopathy In Children 
Rachel J. Wetter, Linda J. Addonizio, Maryanne R. Kichuk, Walton 
M. Gersony, Daphne 1". Hsu. Columbia Universit~, New York, NY 
Restrictive cardiomyopathy (RCM) is a rare entity characterized primarily 
by diastolic dysfunction leading to heart failure (HF). The timing of cardiac 
transplantation (CT) in children with end-2tage RCM has not been well 
defined. The mode of presentation, clinical course and outcome of 13 children 
(9 gifts, 4 boys) with RCM referred for CT were reviewed. Mean age at 
diagnosis was 4.6 yrs. (range 0.1-16 yrs.). The presenting symptom was 
HF in 4 pts, irregular heart rate in 3 lots, heart murmur in 3 pts, dyspnea 
in 2 pts, and syncope in 1 pt. A(I pts had evidence of diastolic dysfunction 
at presentation; 11113 children had preserved systolic function and 2 pts 
had poor systolic function. Significant atrial tachyarrhythmias occurred in 4 
lots (31%); 2 of these pts also developed complete heart block reouinng 
pacemakers. Major embslic events occurred in 2 pts (15%): stroke in 1 pt, 
pulmonary embolus in 1 pt. One lot developed a proteln-lasing entempathy. 
Two pts had unremitting HF from presentation; severe HF developed in the 
remaining 11 pts 3.3 yrs (range 0.3-8.5 yrs) following presentation. Cardiac 
catheterization performed at CT referral (2.8:1:2.4 yrs after presentation) 
demonstrated high filling pressures: LVEDP: 30 ± 9 romHg; RVEDP: 16 :E 
6 mmHg. The mean cardiac index was 2.2 -~ 0.38 IJmin/m2, The mean PA 
pressure was 50 :t: 20 mmHg with a mean pulmonary vascular resistance 
index (PVRI) of 10.8 (range 1.8--30). In 9 lots PVRI was >6 U/m2. The 
mean time to transplant or death in 12/13 pts was 7.3 :E 5 months after 
onset of HF. Four pts died of HF; 3 of these were not candidates for CT 
due to extremely elevated PVRI. CT was perf~,'med in 8 pts with 2 operative 
deaths from pulmonary hypertension and donor dght HF. In summary, HF 
developed late in 11113 (85%) children with RCM, but progressed rapidly. 
Severe pulmonary hypertension was present in 9113 pts (69%) at the time of 
cardiac transplant referral and precluded successful transplant in 5. Cardiac 
catheterization should be performed early In children with RCM to evaluate 
pulmonary vascular resistance and optimize the timing of transplantation. 
4:30 
~ Pediatric Dilated Cardlomyopathy (DCM): Prognosis 
in a Developing Nation Is Comparable to Developed 
Nations 
K. Kumar, D. TI1atsi, A. Saxons, V. Sdnivas, R. Juneja, S.S. Kothari, 
S. Shrivastava, S.E, Lipshuitz. Children's Hospital, Boston, MA; All India 
Institute of Medical Sciences, New Delhi, India 
Mortality from pediatric DCM is 3,3-67% 1-5 yrs after presentation i  studies 
from the US and UK. A Turkish study found 10% mortality over 2 yrs ot follow- 
up of 110 children with DCM. We determined prognosis of pediatric DCM in 
northern India where, compared to the US, 1) pediatric intensive care was 
more limited (e,g., 0.02 vs 1.84 PICU 10ecls/10O,gg0 population in northern 
India vs eastem MA), 2) PICU care was not as sophisticated, and 3) the 
average cost of admission for this diagnosis was less (usually < $200 US). 
128 consecutive children with DCM (77 males, 51 females, median age, 24 
mus, mean age, 46 rues, range, 2-180 rnos) were studied. Multivariate and 
survival analyses were performed on the 97 children with follow-up (mean, 23 
ads, range, 1-96 ads) and included sex, age at onset, delay after onset of 
symptoms, viral illness, CHF, ST-T changes, LVH, cardiothoracic ratio (CTR), 
LVER LA/AO, LV thickness/dimension. At presentation, CHF was noted in 
82% of pt~ and the mean LVEF was 0.41 ~ 0.15. 52 pts (54%) improved on 
therapy and of these, 23 (24%) became symptom-free without medication. 34 
pts worsened despite therapy, and 18 (19%) of these died. Deaths occurred 
within 3 yrs of follow-up. Multivariate analysis shewed tamats sex (RR: 
2.15; 95% CI: 1.07, 2.87), cardiomegaly on presenting CXR (RR for CTR 
> 0,68: 2.24, 95% CI: 1.04, 4.85), and LA enlargement at presentation (RR 
for LA/AO > 1.7: 2.02, 95% Ch 1.00, 4.22) as the variables associated 
with poor outcome (death/worsening). Female sex was the only significant 
univariate and multivariate predictor of death. Conclusions: The prognosis of 
pediatric DCM in northem India is at least comparable to those reported for 
pediatric DCM in developed nations. The prognosis of pediatric DCM may not 
improve without further understanding of its etiologies and the development 
of etioingy-specitic therapies. The developing female myocardium may be 
mere susceptible to damage than the male myocardium. 
4:45 
~- '~  Survival and Risk Factors for Death Alter Cardiac 
Transplantation in Infants: A Multi-lnatltutional 
Study 
Charles Center, David Naftet, Randall Caldwell, Richard Chinnock, 
EIfdeda Patti, Elizabeth Frezier, James Kirklin, Mark Boucak, 
Robert Morrow and the Pediatric Heart Transplant Study Group. Univ. of 
Atabama at Birmingham, B'ham, AL 35294 
Despite the increasing application of cardiac transplantation (C Tx) in infants, 
reported survival rates vary and risk factors for death are poorly understood. 
In order 1o examine early survival and risk factors for death in infants (<t yr 
of age) undergoing C Tx, 142 infants (36 < 1 me) undanNent primary C Tx 
from 1/1/93 to 1/1/95 at 21 canters in the Pediaffic Heart Transplant Study 
(PHTS). Diagnoses were hypoplastic left heart (66°/=), other congenital heart 
disease (170/o), cardiomyapathy (14%) and other (3%). 
Results: Actuarial survival after C Tx was 84% at 1 me, 70°/= at 1 yr, and 
69% at 2 yrs, with the greatest hazard for death in the first 3 ads. The 
principle cause of death was early graft failure in 20 pts (52% of deaths); 
infection in 10 (26% of deaths), and rejection in 4 (19%). The likelihood of 
death from early graft failure (or isolated right venfficular failure) was 130/o 
at 30 days. By multivadable analysis, risk factors for early mortality were 
history of previous stemotomy (p = 0.0003), recipient non-blood group A 
(p = 0.02), non-identical brood donor (p = 0.01), and donor cause of death 
other than closed head trauma (p = 0.04). Survival was favorable in idenfica', 
blood groups with no previous stemotomy (80°/= at I yr). Diagnosis at listing, 
waiting time (mean waiting time 1.3 me), graft ischemic time (range 68 to 
479 minutes, mean 228), and recipient icatropic support at listing were not 
predictive for mOrtality post C Tx. 
Inferences: 
• In the current era, strategies to improve donor heart function at implan. 
tation would have the greatest impact on survival after infant C Tx. 
• If early mortality from acute graft failure could be reduced by 75%, 
anticipated 1yr survival would approach 80°/,,. 
5:00 
J'7"6"7----~ Lelt Ventdcular Fill ing Psttems Predict Acute 
Rejection in Pediatric Heart Transplant Patients 
Douglas C. Sernler, Thomas R. Kimball, Sandra A. Wift. Children's HoSpital 
Medical Center, Cincinnati, Ohio 
Transplant rejection may effect LV diastolic function, Automatic border de- 
tection is a new echo techniql,e which continuously tracks the endocardium, 
allowing global assessment of LV filling. The aim of this study was to deter- 
mine if changes in LV tilling predict rejection in pediatric transplant pattsnts. 
Twelve patients (2-18 y.o.) had echoes at 2 study periods: 1) while healthy 
without rejection and 2) at biopsy-proven rejection. The percent of total LV 
filling due to rapid tilling (pRF), diaeresis (pO) and atrial contraction (pAC) 
were measured by automatic border detection from a parastemat raneveme 
view. Results: The percent of total LV tilling contributed by each diastolic 
phase is presented iP~ the pie charts below: 
pAC FAC 
fOJ~ ILfJ% 
L2~Olll pO 111.4'/, pRF 
.3% pRF 
e l . l% 
Pre.miedon Re|eetion 
pRF decreased (p < 0.10) and pD increased significantly (p < 0.05) dudng 
rejection, pAC and heart rate did not change. 
We speculate that during rejection, inflammation i creases LV stiffness 
